Loading
Life sciences · Journal article
Advanced Science · October 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Late recurrence in gynecologic malignancies is associated with tumor dormancy and persistent minimal residual disease (MRD). Although current treatments reduce proliferating tumor burden, residual cells may survive therapy and drive delayed relapse. This Review examines dormancy in ovarian, endometrial, and cervical cancers using entry, maintenance, and awakening as an organizing framework rather than a universally demonstrated sequence. Direct evidence is concentrated in ovarian cancer, whereas evidence in endometrial and cervical cancers remains predominantly indirect. We delineate candidate biological dependencies—including redox control, lipid peroxidation buffering, mitochondrial plasticity, adaptive stress‐response programs, epigenetic and post‐transcriptional plasticity, immune regulation, and extracellular matrix remodeling—rather than established vulnerabilities. On this basis, we evaluate two biologically distinct investigational concepts: suppression of reactivation‐associated signals to prolong clinical latency, and state modulation followed by biomarker‐defined treatment, discussed within established disease‐specific care pathways. Finally, we propose a translational framework combining longitudinal liquid biopsy with spatial and single‐cell profiling for MRD monitoring, biological stratification, and future probabilistic inference of residual‐cell states. Together, these concepts support a shift from reactive relapse treatment toward evidence‐ and risk‐constrained recurrence‐interception research and provide a framework for validating residual‐state biomarkers and therapeutic dependencies in gynecologic malignancies.